192 related articles for article (PubMed ID: 32658932)
21. Generation of an in vitro 3D PDAC stroma rich spheroid model.
Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
[TBL] [Abstract][Full Text] [Related]
22. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma.
Hiroshima Y; Kasajima R; Kimura Y; Komura D; Ishikawa S; Ichikawa Y; Bouvet M; Yamamoto N; Oshima T; Morinaga S; Singh SR; Hoffman RM; Endo I; Miyagi Y
Cancer Lett; 2020 Jan; 469():217-227. PubMed ID: 31669204
[TBL] [Abstract][Full Text] [Related]
23. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
24. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
[TBL] [Abstract][Full Text] [Related]
25. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
26. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
27. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma.
Chu CK; Mazo AE; Goodman M; Egnatashvili V; Sarmiento JM; Staley CA; Galloway JR; Adsay NV; Jacobs S; Kooby DA
Ann Surg Oncol; 2010 Feb; 17(2):502-13. PubMed ID: 19885697
[TBL] [Abstract][Full Text] [Related]
28. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
29. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
[TBL] [Abstract][Full Text] [Related]
30. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
31. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
32. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM.
Marchegiani G; Andrianello S; Malleo G; De Gregorio L; Scarpa A; Mino-Kenudson M; Maggino L; Ferrone CR; Lillemoe KD; Bassi C; Castillo CF; Salvia R
Ann Surg; 2017 Jul; 266(1):142-148. PubMed ID: 27322188
[TBL] [Abstract][Full Text] [Related]
33. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
34. VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis.
Georgiadou D; Sergentanis TN; Sakellariou S; Filippakis GM; Zagouri F; Vlachodimitropoulos D; Psaltopoulou T; Lazaris AC; Patsouris E; Zografos GC
Eur J Surg Oncol; 2014 Oct; 40(10):1331-7. PubMed ID: 24480377
[TBL] [Abstract][Full Text] [Related]
35. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis.
Huang YK; Liu H; Wang XZ; Zhu S
Asian Pac J Cancer Prev; 2014; 15(22):9921-6. PubMed ID: 25520129
[TBL] [Abstract][Full Text] [Related]
36. Histopathological tumor invasion of the mesenterico-portal vein is characterized by aggressive biology and stromal fibroblast activation.
Lapshyn H; Bolm L; Kohler I; Werner M; Billmann FG; Bausch D; Hopt UT; Makowiec F; Wittel UA; Keck T; Bronsert P; Wellner UF
HPB (Oxford); 2017 Jan; 19(1):67-74. PubMed ID: 27825542
[TBL] [Abstract][Full Text] [Related]
37. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
[TBL] [Abstract][Full Text] [Related]
38. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma.
Kalloger SE; Karasinska JM; Keung MS; Thompson DL; Ho J; Chow C; Gao D; Topham JT; Warren C; Wong HL; Lee MK; Renouf DJ; Schaeffer DF
Int J Cancer; 2021 Jan; 148(2):481-491. PubMed ID: 32955725
[TBL] [Abstract][Full Text] [Related]
39. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
40. Stroma and pancreatic ductal adenocarcinoma: an interaction loop.
Luo G; Long J; Zhang B; Liu C; Xu J; Ni Q; Yu X
Biochim Biophys Acta; 2012 Aug; 1826(1):170-8. PubMed ID: 22521638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
